All IndicationsNeurology & CNSPhase 3Phase 3Phase 3Phase 2
🧠
Alzheimer's Disease
5
Companies
9
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
LLY
Eli Lilly and Company
Remternetug (IV)
JNJ
Johnson & Johnson
galantamine ER
RHHBY
Roche
trontinemab
ABBV
AbbVie Inc.
ABBV-8E12
LLY
Eli Lilly and Company
donanemab-azbt
BIIB
Biogen
diranersen
RHHBY
Roche
Masupirdin
RHHBY
Roche
Masupirdine
BIIB
Biogen
Leqembi
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Remternetug (IV) | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | galantamine ER | Phase 3 | — | — | — |
| RHHBY Roche | trontinemab | Phase 3 | — | — | — |
| ABBV AbbVie Inc. | ABBV-8E12 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | donanemab-azbt | — | — | — | — |
| BIIB Biogen | diranersen | — | — | — | — |
| RHHBY Roche | Masupirdin | — | — | — | — |
| RHHBY Roche | Masupirdine | — | — | — | — |
| BIIB Biogen | Leqembi | — | — | — | — |
Development Stage Distribution
Unknown
5
Phase 3
3
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.